Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

Inclusion Criteria: * Clinical diagnosis of COPD (according to GOLD guidelines) * FEV1 \> or equal 30% and \< 50% of predicted normal post-bronchodilator (and at least 0.7 L absolute value) * COPD symptoms for at least 2 years * At least 1 exacerbation requiring medical intervention (oral corticosteroid and/or antibiotic treatment and/or need for a visit to an emergency department and/or hospitalization) within 2-12 months before screening * Current or previous smoker with a cumulative exposure to smoke of more than 20-pack year Exclusion Criteria: * Current or past diagnosis of asthma, or any evidence suggestive of asthma * Positive FEV1 reversibility test * Clinically significant or unstable concurrent diseases, including clinically significant laboratory abnormalities * Acute COPD exacerbation or lower tract infection and/or treatment with oral or injectable corticosteroids and antibiotics in the 2 months before screening or during run-in * Long term oxygen therapy